Navigation Links
Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs
Date:11/5/2008

nology" of results demonstrating long-term protection against measles challenge in juvenile and infant nonhuman primates with a Vaxfectin(R)-formulated DNA vaccine.

Conference Call

Vical will conduct a conference call and webcast to discuss the financial results and program updates with invited analysts and institutional investors today, November 5, at noon Eastern Time. The call and webcast are open on a listen-only basis to any interested parties. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (800) 817-4887, or (913) 312-1277 for international participants, and reference confirmation code 3255394. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (888) 203-1112, or (719) 457-0820 for international participants, and enter replay passcode 3255394. The call also will be available live and archived through the events page at http://www.vical.com. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at info@vical.com.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results
2. Vical to Present at Upcoming Investor Conferences
3. Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
4. Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
5. Vical to Present at UBS Global Life Sciences Conference
6. Society of Gynecologic Oncologists to Host Cervical Cancer Prevention Forum
7. Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System
8. Vical to Present at Upcoming Investor Conferences
9. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
10. Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
11. One4One Campaign to Raise $1 Million to Improve Cervical Cancer Education and Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... (PRWEB) May 06, 2015 Park ... announced NX-Hivac, the only high vacuum AFM system in ... for failure analysis semiconductor manufacturing. Park NX-Hivac is ideal ... failure analysis solutions in highly doped semiconductor processing where ... , The high vacuum scanning spreading resistance microscopy ...
(Date:5/6/2015)... 2015 The Remedy Group , ... for the specialty pharmacy industry, will be exhibiting, presenting, ... Specialty Pharmacy Summit. The Summit will be held May ... and is the largest annual gathering for the specialty ... from pharmacy providers, pharma/biotech manufacturers, and payers, to learn ...
(Date:5/5/2015)... May 5, 2015 Roka Bioscience, Inc. (NASDAQ: ... testing solutions for the detection of foodborne pathogens,  today announced ... Bank of America Merrill Lynch 2015 Health Care Conference on ... at Encore at the Wynn, Las Vegas NV. ... presentation will be available through the investor relations section of ...
(Date:5/5/2015)... 05, 2015 Research and Markets ... addition of the "Separation Systems Market ... Macromolecules which include protein, RNA, ... are broken into smaller molecules, during production ... requires various advanced systems like centrifugation, liquid ...
Breaking Biology Technology:Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 2Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 3The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2
... CITY, Feb. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... company focused on,endocrine therapy and oncology, today reported ... agonist linked to doxorubicin,has commenced in its Phase ... had begun in December 2007. This open-label,non-comparative multi-center ...
... Candidates Featured -, SOUTH SAN FRANCISCO, Calif., ... company focused on the discovery,and development of monoclonal ... been selected for presentation at the meeting,of American ... Diego on,April 12-16, 2008., "We are pleased ...
... 12 Nektar,Therapeutics (Nasdaq: NKTR ) announced ... a drug delivery service provider to a,therapeutics drug ... corporate functions, and strengthen,decision-making and execution within the ... a world-class drug development company,and these changes are ...
Cached Biology Technology:AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 2AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 3AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 4Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations 2Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations 3Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 2Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 3
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... A world-class St. Augustine spa called “perfect” by past ... a “perfect 10” business opportunity for entrepreneurs with an eye for beauty and ... Designed by renowned ... is part of the highly-rated Laterra Resort, located in the World Golf Village ...
... April 27 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: ... development company specialized in oncology and endocrinology, announced today that ... notifying it that the closing price per share of the ... bid price for 10 consecutive trading days and that, as ...
... be able to survive the harsh environs of Mars ... according to research published in the April 2010 issue ... The search for life on Mars remains a ... Institutes. To preserve the pristine environments, the bioloads on ...
Cached Biology News:Plastic Surgeons Rate Auction of World-Class Florida Laterra Spa May 21 a 'Perfect 10,' Great Business Opp for Celebrity Retreat 2Plastic Surgeons Rate Auction of World-Class Florida Laterra Spa May 21 a 'Perfect 10,' Great Business Opp for Celebrity Retreat 3Plastic Surgeons Rate Auction of World-Class Florida Laterra Spa May 21 a 'Perfect 10,' Great Business Opp for Celebrity Retreat 4
... Tecans state-of-the-art software for all your biopharmaceutical ... in a single, scalable software package. The ... simplifying the control of all Freedom instruments ... EVO 100 with one liquid handling arm ...
... Kit is an advanced system for isolating DNA from ... be used directly for any downstream application. ... to use in 56 minutes Low melting point ... and TBE gels No specialised equipment required ...
... in hybridization incubators with rotators. Graduated, ... size PP plug-seal screw-cap with O-ring ... three lengths to accept different size ... O-rings available separately. • Comp Dim: ...
... efficient extraction of DNA fragments from 150 bp to ... procedure uses GelMelt solution to dissolve the gel slice, ... membrane in a spin column format. After a wash ... Each spin column can bind up to 20 g ...
Biology Products: